Nomograms for Predicting Axillary Response to Neoadjuvant Chemotherapy in Clinically Node-Positive Patients with Breast Cancer-Reference-Cited by-同舟云学术

Nomograms for Predicting Axillary Response to Neoadjuvant Chemotherapy in Clinically Node-Positive Patients with Breast Cancer

Published:2016-05-23 Issue:11 Volume:23 Page:3501-3509
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Vila Jose,Mittendorf Elizabeth A.,Farante Gabriel,Bassett Roland L.,Veronesi Paolo,Galimberti Viviana,Peradze Nicolas,Stauder Michael C.,Chavez-MacGregor Mariana,Litton Jennifer F.,Huo Lei,Kuerer Henry M.,Hunt Kelly K.,Caudle Abigail S.

Funder

Instituto de Salud Carlos III

Fondazione Umberto Veronesi

NCI Cancer Center Support Grant

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

http://link.springer.com/content/pdf/10.1245/s10434-016-5277-1.pdf

Reference33 articles.

1. Kuerer H, Sahin A, Hunt K, et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg. 1999;230:72–8.

2. Buzdar A, Ibrahim N, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005;23:3676–84.

3. Hennessy B, Hortobagyi G, Rouzier R, et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol. 2005;23:9304–11.

4. Dominici L, Negron Gonzalez V, Buzdar A, et al. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer. Cancer. 2010;116:2884–9.

5. Boughey J, Suman V, Mittendorf E, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310:1455–61.

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predicting axillary response to neoadjuvant chemotherapy using peritumoral and intratumoral ultrasound radiomics in breast cancer subtypes;iScience;2024-09

2. Delta Radiomics Based on MRI for Predicting Axillary Lymph Node Pathologic Complete Response After Neoadjuvant Chemotherapy in Breast Cancer Patients;Academic Radiology;2024-09

3. Prediction of breast cancer and axillary positive-node response to neoadjuvant chemotherapy based on multi-parametric magnetic resonance imaging radiomics models;The Breast;2024-08

4. Nomogram Based on US and Clinicopathologic Characteristics: Axillary Nodal Evaluation Following Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer;Clinical Breast Cancer;2024-08

5. Neoadjuvant chemotherapy for breast cancer in Italy: A Senonetwork analysis of 37,215 patients treated from 2017 to 2022;The Breast;2024-08